Interleukin-6 Receptor Signaling and Abdominal Aortic Aneurysm Growth Rates.


Journal

Circulation. Genomic and precision medicine
ISSN: 2574-8300
Titre abrégé: Circ Genom Precis Med
Pays: United States
ID NLM: 101714113

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 19 1 2019
medline: 9 4 2020
entrez: 19 1 2019
Statut: ppublish

Résumé

The Asp358Ala variant (rs2228145; A>C) in the IL (interleukin)-6 receptor ( IL6R) gene has been implicated in the development of abdominal aortic aneurysms (AAAs), but its effect on AAA growth over time is not known. We aimed to investigate the clinical association between the IL6R-Asp358Ala variant and AAA growth and to assess the effect of blocking the IL-6 signaling pathway in mouse models of aortic aneurysm rupture or dissection. Using data from 2863 participants with AAA from 9 prospective cohorts, age- and sex-adjusted mixed-effects linear regression models were used to estimate the association between the IL6R-Asp358Ala variant and annual change in AAA diameter (mm/y). In a series of complementary randomized trials in mice, the effect of blocking the IL-6 signaling pathways was assessed on plasma biomarkers, systolic blood pressure, aneurysm diameter, and time to aortic rupture and death. After adjusting for age and sex, baseline aneurysm size was 0.55 mm (95% CI, 0.13-0.98 mm) smaller per copy of the minor allele [C] of the Asp358Ala variant. Change in AAA growth was -0.06 mm per year (-0.18 to 0.06) per copy of the minor allele; a result that was not statistically significant. Although all available worldwide data were used, the genetic analyses were not powered for an effect size as small as that observed. In 2 mouse models of AAA, selective blockage of the IL-6 trans-signaling pathway, but not combined blockage of both, the classical and trans-signaling pathways, was associated with improved survival ( P<0.05). Our proof-of-principle data are compatible with the concept that IL-6 trans-signaling is relevant to AAA growth, encouraging larger-scale evaluation of this hypothesis.

Sections du résumé

BACKGROUND
The Asp358Ala variant (rs2228145; A>C) in the IL (interleukin)-6 receptor ( IL6R) gene has been implicated in the development of abdominal aortic aneurysms (AAAs), but its effect on AAA growth over time is not known. We aimed to investigate the clinical association between the IL6R-Asp358Ala variant and AAA growth and to assess the effect of blocking the IL-6 signaling pathway in mouse models of aortic aneurysm rupture or dissection.
METHODS
Using data from 2863 participants with AAA from 9 prospective cohorts, age- and sex-adjusted mixed-effects linear regression models were used to estimate the association between the IL6R-Asp358Ala variant and annual change in AAA diameter (mm/y). In a series of complementary randomized trials in mice, the effect of blocking the IL-6 signaling pathways was assessed on plasma biomarkers, systolic blood pressure, aneurysm diameter, and time to aortic rupture and death.
RESULTS
After adjusting for age and sex, baseline aneurysm size was 0.55 mm (95% CI, 0.13-0.98 mm) smaller per copy of the minor allele [C] of the Asp358Ala variant. Change in AAA growth was -0.06 mm per year (-0.18 to 0.06) per copy of the minor allele; a result that was not statistically significant. Although all available worldwide data were used, the genetic analyses were not powered for an effect size as small as that observed. In 2 mouse models of AAA, selective blockage of the IL-6 trans-signaling pathway, but not combined blockage of both, the classical and trans-signaling pathways, was associated with improved survival ( P<0.05).
CONCLUSIONS
Our proof-of-principle data are compatible with the concept that IL-6 trans-signaling is relevant to AAA growth, encouraging larger-scale evaluation of this hypothesis.

Identifiants

pubmed: 30657332
doi: 10.1161/CIRCGEN.118.002413
pmc: PMC6383754
mid: EMS81360
doi:

Substances chimiques

Antibodies 0
Biomarkers 0
IL6R protein, human 0
Interleukin-6 0
Receptors, Interleukin-6 0
Transforming Growth Factor beta 0
Angiotensin II 11128-99-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e002413

Subventions

Organisme : Medical Research Council
ID : MR/L003120/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/18/12/33270
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CS/14/2/30841
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/18/13/33946
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/13/13/30194
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/15/11/31593
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/79120
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/79915
Pays : United Kingdom

Références

Br J Surg. 2016 Aug;103(9):1097-104
pubmed: 27346306
JAMA. 2013 Feb 27;309(8):806-13
pubmed: 23443444
Int J Rheumatol. 2010;2010:720305
pubmed: 20981316
Circulation. 2011 Sep 6;124(10):1118-23
pubmed: 21844079
J Clin Invest. 2010 Feb;120(2):422-32
pubmed: 20101093
BMJ. 2005 Apr 2;330(7494):750
pubmed: 15757960
Biochim Biophys Acta. 2014 Sep;1842(9):1485-94
pubmed: 24878322
N Engl J Med. 2017 Nov 9;377(19):1894-1896
pubmed: 29117496
Int J Hematol. 2009 Jul;90(1):99-102
pubmed: 19554396
Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2171-2181
pubmed: 28912363
Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2605-13
pubmed: 16973970
Nature. 2012 Aug 23;488(7412):508-511
pubmed: 22801493
Lancet. 2011 Sep 10;378(9795):1006-14
pubmed: 21907864
Lancet. 2005 Apr 30-May 6;365(9470):1577-89
pubmed: 15866312
Lancet. 2008 Mar 22;371(9617):987-97
pubmed: 18358926
Nat Genet. 2016 Oct;48(10):1151-1161
pubmed: 27618447
Nat Genet. 2012 Dec;44(12):1336-40
pubmed: 23143596
Circulation. 2008 Dec 2;118(23):2382-92
pubmed: 19047592
Cytokine. 2009 May;46(2):211-5
pubmed: 19251434
Eur J Vasc Endovasc Surg. 2009 Dec;38(6):748-9
pubmed: 19666232
Circulation. 2004 Jul 6;110(1):16-21
pubmed: 15210603
Eur J Vasc Endovasc Surg. 2013 Oct;46(4):453-9
pubmed: 23978561
J Immunol. 2008 Jun 1;180(11):7102-6
pubmed: 18490707
Cochrane Database Syst Rev. 2015 Feb 08;(2):CD001835
pubmed: 25927098
Nat Rev Cardiol. 2017 Aug;14(8):457-471
pubmed: 28406184
Ann Intern Med. 1995 Apr 1;122(7):502-7
pubmed: 7872584
Nat Rev Drug Discov. 2018 Jun;17(6):395-412
pubmed: 29725131
Crit Care Med. 2011 Jun;39(6):1407-13
pubmed: 21336117
PLoS Genet. 2013 Apr;9(4):e1003444
pubmed: 23593036
Eur Heart J. 2013 Dec;34(48):3707-16
pubmed: 23111417
J Vasc Surg. 2009 Jan;49(1):178-84
pubmed: 18829218
Nat Rev Cardiol. 2009 Aug;6(8):543-52
pubmed: 19546866
Am J Hum Genet. 2011 Nov 11;89(5):619-27
pubmed: 22055160
Circ Cardiovasc Genet. 2017 Oct;10(5):
pubmed: 28986451
J Clin Invest. 2013 Mar;123(3):1019-31
pubmed: 23426178
Nat Rev Cardiol. 2011 Feb;8(2):92-102
pubmed: 21079638
Atherosclerosis. 2011 Jul;217(1):57-63
pubmed: 21596379
Clin Rheumatol. 2016 Nov;35(11):2657-2661
pubmed: 27502778
Br J Surg. 2009 Aug;96(8):870-7
pubmed: 19591171
JAMA Intern Med. 2016 Dec 1;176(12):1761-1767
pubmed: 27802493
Nat Rev Rheumatol. 2017 Jul;13(7):399-409
pubmed: 28615731
Eur J Cell Biol. 2011 Jun-Jul;90(6-7):484-94
pubmed: 21145125
Lancet. 2012 Mar 31;379(9822):1205-13
pubmed: 22421339
Circ Cardiovasc Genet. 2011 Oct;4(5):557-64
pubmed: 21846873
PLoS One. 2016 Jan 19;11(1):e0147088
pubmed: 26783750
Circulation. 2005 Jun 14;111(23):3119-25
pubmed: 15939823

Auteurs

Ellie Paige (E)

National Centre for Epidemiology and Population Health, Research School of Population Health, The Australian National University, Canberra, Australia (E.P.).
BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care (E.P., M.S., J.E.P., B.B.S., A.S.B., J.D., D.F.F., D.S.P.), University of Cambridge, United Kingdom.

Marc Clément (M)

Division of Cardiovascular Medicine (M.C., F.L., J.R., C.G., A.F., J.H., Z.M.), University of Cambridge, United Kingdom.

Fabien Lareyre (F)

Division of Cardiovascular Medicine (M.C., F.L., J.R., C.G., A.F., J.H., Z.M.), University of Cambridge, United Kingdom.
Université Côte d'Azur, Institut National de la Sante et de la Recherche Medicale, Centre Mediterranéen de Recherche Moleculaire (F.L., J.R.).
University Hospital of Nice, France (F.L., J.R.).

Michael Sweeting (M)

BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care (E.P., M.S., J.E.P., B.B.S., A.S.B., J.D., D.F.F., D.S.P.), University of Cambridge, United Kingdom.
Department of Health Sciences (M.S.), University of Leicester.

Juliette Raffort (J)

Division of Cardiovascular Medicine (M.C., F.L., J.R., C.G., A.F., J.H., Z.M.), University of Cambridge, United Kingdom.
Université Côte d'Azur, Institut National de la Sante et de la Recherche Medicale, Centre Mediterranéen de Recherche Moleculaire (F.L., J.R.).
University Hospital of Nice, France (F.L., J.R.).

Céline Grenier (C)

Division of Cardiovascular Medicine (M.C., F.L., J.R., C.G., A.F., J.H., Z.M.), University of Cambridge, United Kingdom.

Alison Finigan (A)

Division of Cardiovascular Medicine (M.C., F.L., J.R., C.G., A.F., J.H., Z.M.), University of Cambridge, United Kingdom.

James Harrison (J)

Division of Cardiovascular Medicine (M.C., F.L., J.R., C.G., A.F., J.H., Z.M.), University of Cambridge, United Kingdom.

James E Peters (JE)

BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care (E.P., M.S., J.E.P., B.B.S., A.S.B., J.D., D.F.F., D.S.P.), University of Cambridge, United Kingdom.
British Heart Foundation Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, UK (J.E.P., A.S.B., S.C.H., J.D., D.F.F., D.S.P., Z.M.).

Benjamin B Sun (BB)

BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care (E.P., M.S., J.E.P., B.B.S., A.S.B., J.D., D.F.F., D.S.P.), University of Cambridge, United Kingdom.

Adam S Butterworth (AS)

BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care (E.P., M.S., J.E.P., B.B.S., A.S.B., J.D., D.F.F., D.S.P.), University of Cambridge, United Kingdom.
British Heart Foundation Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, UK (J.E.P., A.S.B., S.C.H., J.D., D.F.F., D.S.P., Z.M.).
NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Cambridge, United Kingdom (A.S.B., J.D.).

Seamus C Harrison (SC)

Department of Cardiovascular Sciences, NIHR Leicester Biomedical Research Centre (S.C.H., M.J.B.), University of Leicester.
British Heart Foundation Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, UK (J.E.P., A.S.B., S.C.H., J.D., D.F.F., D.S.P., Z.M.).

Matthew J Bown (MJ)

Department of Cardiovascular Sciences, NIHR Leicester Biomedical Research Centre (S.C.H., M.J.B.), University of Leicester.

Jes S Lindholt (JS)

Department of Cardiovascular and Thoracic Surgery, Elitary Research Centre of Individualised Medicine in Arterial Disease, Odense University Hospital, Denmark (J.S.L.).

Stephen A Badger (SA)

Regional Vascular Surgery Unit, Belfast Health and Social Care Trust, United Kingdom (S.A.B.).

Iftikhar J Kullo (IJ)

Department of Cardiovascular Medicine, Gonda Vascular Center, Mayo Clinic, Rochester, MN (I.J.K.).

Janet Powell (J)

Faculty of Medicine, Department of Surgery and Cancer, Imperial College London, United Kingdom (J.P.).

Paul E Norman (PE)

Medical School, University of Western Australia, Perth, Australia (P.E.N.).

D Julian A Scott (DJA)

Leeds Vascular Institute, Leeds General Infirmary (D.J.A.S., M.A.B.).
Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, United Kingdom (D.J.A.S., M.A.B.).

Marc A Bailey (MA)

Leeds Vascular Institute, Leeds General Infirmary (D.J.A.S., M.A.B.).
Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, United Kingdom (D.J.A.S., M.A.B.).

Stefan Rose-John (S)

Department of Biochemistry, Christian-Albrechts-University, Kiel, Germany (S.R.-J.).

John Danesh (J)

BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care (E.P., M.S., J.E.P., B.B.S., A.S.B., J.D., D.F.F., D.S.P.), University of Cambridge, United Kingdom.
British Heart Foundation Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, UK (J.E.P., A.S.B., S.C.H., J.D., D.F.F., D.S.P., Z.M.).
NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Cambridge, United Kingdom (A.S.B., J.D.).
Department of Human Genetics, Wellcome Sanger Institute, Hinxton, United Kingdom (J.D.).

Daniel F Freitag (DF)

BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care (E.P., M.S., J.E.P., B.B.S., A.S.B., J.D., D.F.F., D.S.P.), University of Cambridge, United Kingdom.
British Heart Foundation Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, UK (J.E.P., A.S.B., S.C.H., J.D., D.F.F., D.S.P., Z.M.).

Dirk S Paul (DS)

BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care (E.P., M.S., J.E.P., B.B.S., A.S.B., J.D., D.F.F., D.S.P.), University of Cambridge, United Kingdom.
British Heart Foundation Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, UK (J.E.P., A.S.B., S.C.H., J.D., D.F.F., D.S.P., Z.M.).

Ziad Mallat (Z)

Division of Cardiovascular Medicine (M.C., F.L., J.R., C.G., A.F., J.H., Z.M.), University of Cambridge, United Kingdom.
British Heart Foundation Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, UK (J.E.P., A.S.B., S.C.H., J.D., D.F.F., D.S.P., Z.M.).
Institut National de la Santé et de la Recherche Médicale, Paris Cardiovascular Research Center, France (Z.M.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH